Viking Therapeutics Data From Phase 2 VENTURE Clinical Study Of VK2735 Demonstrated Improvement In Cardiometabolic Parameters In Participants, Reductions In Prevalence Of Prediabetes And MetS At Week 13

Author: Benzinga Newsdesk | November 06, 2025 07:25am

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in a poster presentation at ObesityWeek® 2025, the annual meeting of The Obesity Society.  VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic disorders.  Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials. 

Results of an exploratory analysis of data from the company's Phase 2 VENTURE clinical trial of VK2735 dosed as a weekly subcutaneous injection were presented in a poster session on Thursday afternoon.  The exploratory analysis evaluated the impact of VK2735 treatment on the prevalence of prediabetes and metabolic syndrome (MetS) following the 13-week study.  Treatment with VK2735 was shown to improve cardiometabolic parameters in patients, including reductions in the prevalence of prediabetes and MetS at the end of the 13-week treatment period.

Data from the study showed that 78% of VK2735-treated patients who were characterized as prediabetic at baseline had successfully shifted to normal glycemic status at Week 13, as compared to 29% for placebo patients (p=0.0008). 

Posted In: VKTX